Q1 2026 EPS Estimates for Puma Biotechnology, Inc. Increased by Zacks Research (NASDAQ:PBYI)

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Stock analysts at Zacks Research boosted their Q1 2026 EPS estimates for shares of Puma Biotechnology in a research report issued on Wednesday, August 28th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. During the same period in the previous year, the company posted $0.05 earnings per share.

PBYI has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, August 2nd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $2.38 on Monday. The business has a 50 day simple moving average of $3.23 and a 200 day simple moving average of $4.26. The stock has a market cap of $114.81 million, a price-to-earnings ratio of 7.21 and a beta of 1.09. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. Puma Biotechnology has a 52-week low of $2.13 and a 52-week high of $7.73.

Insider Buying and Selling

In other news, Director Michael Patrick Miller sold 23,358 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now owns 47,000 shares of the company’s stock, valued at approximately $164,030. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Troy Edward Wilson sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $3.33, for a total transaction of $89,910.00. Following the transaction, the director now directly owns 350 shares of the company’s stock, valued at approximately $1,165.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the sale, the director now directly owns 47,000 shares of the company’s stock, valued at approximately $164,030. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,263 shares of company stock worth $376,379. Corporate insiders own 23.70% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

Several hedge funds have recently bought and sold shares of PBYI. Great Point Partners LLC bought a new stake in shares of Puma Biotechnology during the 4th quarter worth approximately $4,734,000. American Century Companies Inc. boosted its holdings in shares of Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after purchasing an additional 366,653 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of Puma Biotechnology in the 2nd quarter valued at $815,000. Frazier Life Sciences Management L.P. increased its stake in shares of Puma Biotechnology by 8.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after purchasing an additional 246,264 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Puma Biotechnology by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 120,104 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.